Antisense compounds and uses thereof

US9714288B2 · kind B2 · utility

Assignees

• The Regents of the University of California · US
• Ionis Pharmaceuticals, Inc. · US

Inventors

• Michael Oestergaard · Carlsbad, US
• Punit P. Seth · Carlsbad, US
• Shuling Guo · Carlsbad, US
• Noriko Satake · Osaka, JP
• Nitin Nitin · Helotes, US
• Joseph Tuscano · Folsom, US

Key dates

• Filing date: Sep 30, 2015
• Grant date: Jul 25, 2017
• Expiry date: Sep 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/346
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds comprising modified oligonucleotides and anti-CD22 antibodies. Certain such modified oligonucleotides conjugated to anti-CD22 antibodies are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.